期刊文献+

急性下肢深静脉血栓治疗前后VEINES-QOL/Sym调查问卷评分变化 被引量:3

原文传递
导出
摘要 目的观察急性下肢深静脉血栓形成患者治疗前、后静脉功能不全的流行病学和经济研究(Venous Insufficiency Epidemiological and Economic Studies,VEINES)-生活质量(the quality of life,QOL)/症状(symptom,Sym)调查问卷评分水平变化。方法急性下肢深静脉血栓形成患者56例,均给予低分子肝素+尿激酶+华法林治疗,比较治疗前及经治疗华法林用量稳定后VEINES-QOL/Sym问卷评分。结果治疗前、后VEINES-QOL评分分别为(38.23±1.48),(85.14±1.73)分,差异有统计学意义(t=-21.99,P<0.01);治疗前、后VEINES-Sym评分分别为(19.55±0.78),(40.64±0.86)分,差异有统计学意义(t=-17.51,P<0.01)。结论 VEINES-QOL/Sym评分可用于评估急性下肢深静脉血栓患者的治疗效果。
出处 《中华实用诊断与治疗杂志》 2013年第2期206-207,共2页 Journal of Chinese Practical Diagnosis and Therapy
  • 相关文献

参考文献5

二级参考文献40

  • 1熊立凡,王鸿利.D-二聚体与静脉血栓症诊断——循证实验诊断学举例[J].诊断学理论与实践,2005,4(1):75-79. 被引量:35
  • 2呼兵,阮翊,杨运方,王勇.腹腔镜手术后下肢静脉血栓形成临床分析[J].实用诊断与治疗杂志,2006,20(6):457-458. 被引量:4
  • 3刘林涛,马宝通.Prophylaxis against venous thromboembolism in orthopedic surgery[J].Chinese Journal of Traumatology,2006,9(4):249-256. 被引量:4
  • 4Sillesen H,Just S,Jorgensen M,et al.Catheter directed thrombolysis for treatment of ilio-femoral deep venous thrombosis is durable,preserves venous valve function and may prevent chronic venous insufficiency.Eur J Vase Endovese Surg,2005,30:556-562.
  • 5Park YJ,Choi JY,Min SK,et al.Restoration of patency in iliofemoral deep vein thrombosis with catheter-direeted thrombolysis does not always prevent post-thrombotic damage.Eur J Vase Endovasc Surg,2008,36:725-730.
  • 6Vedanthum S,Vesely TM,Patti N,et al.Lower extremity venous thrombolysis with adjunctive mechanicel thrembectomy.J Vasc Interv Redid,2002,13:1001-1008.
  • 7Kusirajan K,Gray B,Ouriel K.Percutaneous angioJet thrombectomy in the management of extensive deep venous thrombosis.J Vaac Interv Radiol,2001,12:179-185.
  • 8Kwon SH,Oh JH,Seo TS,et al.Percutaneous aspiration thrombectomy for the treatment of acute lower extremity deep vein thrombosis:is thrombolysis needed? Clin Radiol,2009,64:484-490.
  • 9Hilleman DE,Razavi MK.Clinical and economic evaluation of the Trellis-8 infusion catheter for deep vein thrombeeis.J vasc Interv Rediol,2008,19:377-383.
  • 10Eklof B,Kasirajan K.Treating proximal deep vein thrombosis.Endovaseular Today,2003,17-23.

共引文献32

同被引文献35

  • 1陈有生,王素伟,钟波,赖晓敏.间歇充气加压预防髋膝关节术后下肢深静脉血栓形成的疗效评价[J].中华临床医师杂志(电子版),2011,5(6):1756-1758. 被引量:13
  • 2Johnson EG, Horne BD, Carlquist JF. Genotype based dosing algorithms for warfarin therapy: data review and recommendationsI-J~. Mol Diagn Ther,2011,15(5) :255 264.
  • 3Gage BF, Eby C, Johnson JA. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarinFJ]. Clin Pharmaeol Ther, 2(308,84(3) : 326-331.
  • 4Klein TE, Altman RB, Eriksson N. Estimation of the warfarindose with clinical and pharmacogenetic data[J]. N Engl J Med, 2009,360(8) :753-764.
  • 5Cen HJ, Zeng WT, Leng XY. CYP4F2 rs2108622: a minor significant genetic factor of warfarin dose in Han Chinese patients with mechanical heart valve replacement[J]. Br J Clin Pharmacol, 2010,70(2) :234-240.
  • 6Gu Q, Kong Y, Schneede J. VKORC1-1639G>A, CYP2Cg, EPHX1691A~G genotype, body weight, and age are important predictors for warfarin maintenance doses in patients with mechanical heart valve prostheses in southwest China[J~. Eur J Clin Pharmacol, 2010,66(12) : 1217-1227.
  • 7Zhong SL, Yu XY, Liu Y. Integrating interacting drugs and genetic variations to improve the predictability of warfarin maintenance dose in Chinese patients E J]. Pharmacogenet Genomics, 2012,22(3) :176-182.
  • 8Finkelman BS, Gage BF, Johnson JA. Genetic warfarin dosing: tables versus algorithms [J 1. J Am Coll Cardiol, 2011,57 ( 5 ) : 612-618.
  • 9Johnson JA, Gong L, Whirl Carrillo M. Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosingEJ]. Clin Pharmacol Ther,2011,90(4) :625-629.
  • 10Anderson JL, Horne BD, Stevens SM. A randomized and clinical effectiveness trial comparing two pharmacogenetic algorithms and standard care for individualizing warfarin dosing (CoumaGen- l] )[J]. Circulation,2012,125(16) ~ 1997-2005.

引证文献3

二级引证文献25

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部